


What is claimed is:

1. A targeting compound of Formula II



or a pharmaceutically acceptable salt thereof, wherein

M^1 is an alpha-emitting radionuclide;

Z^1 is H or $-L^3-R^{22}$

Z^2 is OH or $NH-L^4-R^{24}$

Z^3 is H or $-L^6-R^{28}$;

α is 0 or 1;

X^1 is O, NH, or S;

L^3 , L^4 , L^5 , and L^6 are independently at each occurrence a bond or a linker group; and

R^{22} , R^{24} , R^{26} , and R^{28} each independently comprises an antibody, antibody fragment, a


Fibroblast Activation Protein alpha (FAP-alpha) binding moiety, a binding peptide, a binding polypeptide, a binding protein, an enzyme, a nucleobase-containing moiety, or a lectin.

2. The targeting compound of claim 1, wherein M^1 is actinium-225 ($^{225}\text{Ac}^{3+}$), radium-223 ($^{223}\text{Ra}^{2+}$), bismuth-213 ($^{213}\text{Bi}^{3+}$), lead-212 ($^{212}\text{Pb}^{2+}$ and/or $^{212}\text{Pb}^{4+}$), terbium-149 ($^{149}\text{Tb}^{3+}$), fermium-255 ($^{255}\text{Fm}^{3+}$), thorium-227 ($^{227}\text{Th}^{4+}$), thorium-226 ($^{226}\text{Th}^{4+}$), astatine-211 ($^{211}\text{At}^+$), astatine-217 ($^{217}\text{At}^+$), or uranium-230.

3. The targeting compound of claim 1, wherein R^{22} , R^{24} , R^{26} , and R^{28} each independently comprise belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab,

Atezolizumab, Avelumab, Durvalumab, Capromab pendetide, Elotuzumab, Denosumab, Ziv-aflibercept, Bevacizumab, Ramucirumab, Tositumomab, Gemtuzumab ozogamicin, Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab, Catumaxomab, Etaracizumab, an antigen-binding fragment of any thereof, a prostate specific membrane antigen (“PSMA”) binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment of any thereof.

4. A composition comprising a pharmaceutically acceptable carrier and a targeting compound of claim 1.
5. The targeting compound of claim 1, wherein the targeting compound is represented by the following structure



or a pharmaceutically acceptable salt thereof, chelating the alpha-emitting radionuclide.

6. The targeting compound of claim 5 chelating $^{213}\text{Bi}^{3+}$, $^{211}\text{At}^{+}$, $^{225}\text{Ac}^{3+}$, $^{152}\text{Dy}^{3+}$, $^{212}\text{Bi}^{3+}$, $^{211}\text{Bi}^{3+}$, $^{217}\text{At}^{+}$, $^{227}\text{Th}^{4+}$, $^{226}\text{Th}^{4+}$, $^{233}\text{Ra}^{2+}$, $^{212}\text{Pb}^{2+}$, or $^{212}\text{Pb}^{4+}$.